Total synthesis and evaluation of [Ψ[CH2NH]Tpg 4]vancomycin aglycon: Reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding

Journal of the American Chemical Society

Volumn 128, Issue 9, 2006, Pages 2885-2892

  Crowley, Brendan M ^a   Boger, Dale L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; CARBON; CHEMICAL BONDS; CHEMICAL MODIFICATION; REACTION KINETICS; STEREOCHEMISTRY; SUBSTITUTION REACTIONS; SYNTHESIS (CHEMICAL);

GLYCOPEPTIDE; METHYLENE; VANCOMYCIN AGLYCON;

ESTERS;

ALANINE DERIVATIVE; AMIDE; CARBENE; CARBONYL DERIVATIVE; ESTER; GLYCOPEPTIDE; PEPTIDOGLYCAN; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; VANCOMYCIN DERIVATIVE;

AMINATION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CELL WALL; BINDING AFFINITY; CHEMICAL REACTION; CHEMICAL REACTION KINETICS; CROSS COUPLING REACTION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENGINEERING; MACROLACTAMIZATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REDUCTION; ROOM TEMPERATURE; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; SUZUKI REACTION;

ALANINE; DIPEPTIDES; KINETICS; LACTATES; OLIGOPEPTIDES; VANCOMYCIN;

EID: 33644932823     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja0572912     Document Type: Article

References (58)

1. Reviews: (a) Kahne, D.; Leimkuhler, C.; Lu, W.; Walsh, C. Chem. Rev. 2004, 105, 425.
2. (b) Hubbard, B. K.; Walsh, C. T. Angew. Chem., Int. Ed. 2003, 42, 730.
3. (c) Nicolaou, K. C.; Boddy, C. N. C.; Erase, S.; Winssinger, N. Angew. Chem., Int. Ed. 1999, 38, 2096.
4. (d) Williams, D. H.; Bardsley, B. Angew. Chem., Int. Ed. 1999, 38, 1172.
5. (e) Malabarba, A.; Nicas, T. I.; Thompson, R. C. Med. Res. Rev. 1997, 17, 69.
6. Glycopeptide resistance and analogues: (f) Malabarba, A.; Ciabatti, R. Curr. Med. Chem. 2001, 8, 1759.
7. (g) Pootoolal, J.; Neu, J.; Wright, G. D. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 381.
8. (h) Van Bambeke, F. V.; Laethem, Y. V.; Courvalin, P.; Tulkens, P. M. Drugs 2004, 64, 913.
9. (i) Sussmuth, R. D. ChemBioChem 2002, 3, 295.
10. (j) Gao, Y. Nat. Prod. Rep. 2002, 19, 100.
11. (k) Healy, V. L.; Lessard, I. A. D.; Roper, D. I.; Knox, J. R.; Walsh, C. T. Chem. Biol. 2000, 7, R109.
12. McComas, C. C.; Crowley, B. M.; Boger, D. L. J. Am. Chem. Soc. 2003, 125, 9314.
13. Efforts to modify the residue 4 carbonyl by selective reaction of the amide linking residues 4 and 5 within vancomycin aglycon derivatives have not yet been successful in our efforts, and we are unaware of any reports of such modifications. Synthetic reviews: (a) Boger, D. L. Med. Res. Rev. 2001, 21, 356.
14. (b) Lloyd-Williams, P.; Giralt, E. Chem. Soc. Rev. 2001, 30, 145.
15. (c) Zhang, A. J.; Burgess, K. Angew. Chem., Int. Ed. 1999, 38, 634.
16. (d) Rao, A. V. R.; Gurjar, M. K.; Reddy, K. L.; Rao, A. S. Chem. Rev. 1995, 95, 2135.
17. (e) Evans, D. A.; DeVries, K. M. Drugs Pharm. Sci. 1994, 63, 63.
18. (a) Boger, D. L.; Miyazaki, S.; Kim, S. H.; Wu, J. H.; Loiseleur, O.; Castle, S. L. J. Am. Chem. Soc. 1999, 121, 3226.
19. (b) Boger, D. L.; Miyazaki, S.; Kim, S. H.; Wu, J. H.; Castle, S. L.; Loiseleur, O.; Jin, Q. J. Am. Chem. Soc. 1999, 121, 10004.
20. (a) Boger, D. L.; Kim, S. H.; Miyazaki, S.; Strittmatter, H.; Weng, J.-H.; Mori, Y.; Rogel, O.; Castle, S. L.; McAtee, J. J. J. Am. Chem. Soc. 2000, 122, 7416.
21. (b) Boger, D. L.; Kim, S. H.; Mori, Y.; Weng, J.-H.; Rogel, O.; Castle, S. L.; McAtee, J. J. J. Am. Chem. Soc. 2001, 123, 1862.
22. Crowley, B. M.; Mori, Y.; McComas, C. C.; Tang, D.; Boner, D. L. J. Am. Chem. Soc. 2004, 126, 4310.
23. (a) Boger, D. L.; Borzilleri, R. M.; Nukui, S.; Beresis, R. T. J. Org. Chem. 1997, 62, 4721.
24. (b) Boger, D. L.; Borzilleri, B.; Nukui, S. J. Org. Chem. 1996, 61, 3561.
25. (c) Boger, D. L.; Castle, S. L.; Miyazaki, S.; Wu, J. H.; Beresis, R. T.; Loiseleur, O. J. Org. Chem. 1999, 64, 70.
26. (d) Boger, D. L.; Loiseleur. O.; Castle, S. L.; Beresis, R. T.; Wu, J. H. Bioorg. Med. Chem. Lett. 1997, 7, 3199.
27. (e) Boger, D. L.; Beresis, R. T.; Loiseleur, O.; Wu, J. H.; Castle, S. L. Bioorg. Med. Chem. Lett. 1998, 8, 721.
28. (f) Boger, D. L.; Miyazaki, S.; Loiseleur, O.; Wu, J. H.; Jin, Q. J. Am. Chem. Soc. 1998, 120, 8920.
29. Boger, D. L.; Borzilleri, R. M.; Nukui, S. Bioorg. Med. Chem. Lett. 1995, 5, 3091.
30. Evans, D. A.; Watson, P. S. Tetrahedron Lett. 1996, 37, 3251.
31. (a) Evans, D. A.; Wood, M. R.; Trotter, B. W.; Richardson, T. I.; Barrow. J. C.; Katz, J. L. Angew. Chem., Int. Ed. 1998, 37, 2700.
32. (b) Evans, D. A.; Dinsmore, C. J.; Watson, P. S.; Wood, M. R.; Richardson, T. I.; Trotter, B. W.; Katz, J. L. Angew. Chem., Int. Ed. 1998, 37, 2704.
33. Solladié-Cavallo, A.; Nsenda, T. Tetrahedron Lett. 1998, 39, 2191.
34. Compound 7 is available in six steps (37% overall) from methyl gallate using three recrystallizations and was scaled to 300 g, ref 6.
35. Compound 6 is available in five steps (55% overall) from (R)-4-hydroxyphenyl-glycine using two recrystallizations and was scaled to 60 g, ref 7a.
36. Benzyl ether deprotection at higher temperatures (25 °C) may lead to competitive aryl bromide reduction, although this was observed in appreciable amounts only when excess Raney nickel was employed.
37. Saponification of 11 was considerably slower than that of 10 and occasionally required additional LiOH for complete conversion to 12, with little effect on the amount of epimer generated in the reaction.
38. Compound 13 is available in three steps (45% overall) from 4-fluoro-3-nitrobenzaldehyde and was scaled to 30 g, ref 6.
39. Fan, C.-X.; Hao, X.-L.; Ye, Y.-H. Synth. Commun. 1996, 26, 1455.
40. Li, H.; Jiang, X.; Ye, Y.-H.; Fan, C.; Romoff, T.; Goodman, M. Org. Lett. 1999, 1, 91.
41. Recent efforts have led to improvements in the vancomycin CD ring closure, and this method was utilized for the preparation of the analogous intermediates bearing a residue 4/5 thioamide. Its use in the preparation of 5 along with additional vancomycin analogues will be disclosed in due time.
42. Use of Raney nickel for N-Cbz removal was also successful, although lower recoveries (84%) of the product were observed.
43. 2.
44. (a) Nicolaou, K. C.; Takayanagi, M.; Jain, N. F.; Natarajan, S.; Koumbis, A. E.; Bando, T.; Ramanjulu, J. M. Angew. Chem., Int. Ed. 1998, 37, 2717.
45. (b) Nicolaou, K. C.; Natarajan, S.; Li, H.; Jain, N. F.; Hughes, R.; Solomon, M. E.; Ramanjulu, J. M.; Boddy, C. N. C.; Takayanagi, M. Angew. Chem., Int. Ed. 1998, 37, 2708.
46. (c) Nicolaou, K. C.; Jain, N. F.; Natarajan, S.; Hughes, R.; Solomon, M. E.; Li, H.; Ramanjulu, J. M.; Takayanagi, M.; Koumbis, A. E.; Bando, T. Angew. Chem., Int. Ed. 1998, 37, 2714.
47. (d) Nicolaou, K. C.; Mitchell, H. J.; Jain, N. F.; Winssinger, N.; Hughes, R.; Bando, T. Angew. Chem., Int. Ed. 1999, 38, 240.
48. (e) Nicolaou, K. C.; Li, H.; Boddy, C. N. C.; Ramanjulu, J. M.; Yue, T.-Y.; Natarajan, S.; Chu, X.-J.; Brase, S.; Rubsam, F. Chem. Eur. J. 1999, 5, 2584.
49. (f) Nicolaou, K. C; Boddy, C. N. C.; Li, H.; Koumbis, A. E.; Hughes, R.; Natarajan, S.; Jain, N. F.; Ramajulu, J. M.; Brase, S.; Solomon, M. E. Chem. Eur. J. 1999, 5, 2602.
50. (g) Nicolaou, K. C.; Koumbis, A. E.; Takayanagi, M.; Natarajan, S.; Jain, N. F.; Bando, T.; Li, H.; Hughes, R. Chem. Eur. J. 1999, 5, 2622.
51. (h) Nicolaou, K. C.; Mitchell, H. J.; Jain, N. F.; Bando, T.; Hughes, R.; Winssinger, N.; Natarajan, S.; Koumbis, A. E. Chem. Eur. J. 1999, 5, 2648.
52. Reduction of the nitro group was sensitive to the choice of solvent in terms of recovery and observance of side products.
53. Node, M.; Nishide, K.; Fuji, K.; Fujita, E. J. Org. Chem. 1980, 45, 4275.
54. Evans, D. A.; Ellman, J. A. J. Am. Chem. Soc. 1989, 111, 1063.
55. Nieto, M.; Perkins, H. R. Biochem. J. 1971, 124, 845.
56. Nieto, M.; Perkins, H. R. Biochem. J. 1971, 124, 773.
57. Nieto, M.; Perkins, H. R. Biochem. J. 1971, 124, 789.
58. McAtee, J. J.; Castle, S. L.; Jin, Q.; Boner, D. L. Bioorg. Med. Chem. Lett. 2002, 12, 1319.